|Status : Published||Published On : Dec, 2021||Report Code : VRHC1043||Industry : Healthcare||Available Format :||Page : 200|
The global non-invasive prenatal testing (NIPT) market was valued at USD 2.8 billion in 2021 and is anticipated to reach USD 6.83 billion by 2030, witnessing a CAGR of 12.35% during 2022-2030. Non-invasive prenatal testing (NIPT) is a sensitive diagnosis method for identifying specific chromosomal abnormalities in the developing fetus. Chromosomal disorders such as Turner syndrome, Edwards syndrome, Patau syndrome, and down syndrome are some of the diseases which are screened using NIPT. The global non-invasive prenatal testing market is growing at a significant rate, due to mounting occurrence of chromosomal abnormalities, mounting maternal age and introduction of advanced products. Different products contributed to the non-invasive prenatal testing market size. The market has witnessed a high demand for consumables over the last few years due to repeated supplies of consumables as compared to instruments.
Insight by Product
On the basis of product, the market is subdivided into instruments and consumables. Repeated supplies of consumables are the factors responsible for the growth of the consumables segment. Of both the products, the consumables account the foremost share in the non-invasive prenatal testing market. The instruments market is further subdivided into next-generation sequencing systems, microarrays, ultrasound devices, polymerase chain reaction instruments, and others. In addition, consumables are further subdivided into disposables and assay kits & reagents
Insight by Method
On the basis of method, the market is subdivided into cell-free DNA in maternal plasma tests, ultrasound detection, fetal cell in maternal blood tests, and biochemical screening tests. Mounting need for cell free-DNA based techniques and expanding government schemes to offer prenatal services are the factors growing the demand for cell-free DNA in maternal plasma tests. Among all methods, the cell-free DNA in maternal plasma tests is expected to grow at the fastest rate in the non-invasive prenatal testing market. In addition, ultrasound detection segment accounted for the largest share in the market.
Insight by Application
On the basis of application, the market is subdivided into microdeletion syndrome, trisomy, and others. Increasing occurrence of chromosomal abnormalities with mounting maternal age is the factor responsible for the growth of the trisomy segment. Of all the applications, the trisomy accounted for the largest share and is expected to grow at the fastest rate in the non-invasive prenatal testing market.
Insight by End User
On the basis of end-user, the market is subdivided into hospitals and diagnostic laboratories. Mounting occurrence of chromosomal abnormalities and mounting schemes by companies to provide advanced products to diagnostic laboratories are some of the factors responsible for the growth of the diagnostic laboratories segment. Of both end-users, the diagnostic laboratories accounted for the largest share in the non-invasive prenatal testing market.
The refining reimbursement scenario for NIPT, mounting occurrence of chromosomal abnormalities, Mounting average maternal age, and introduction of advanced products are the primary growth drivers for the non-invasive prenatal testing market. For instance, according to the World Health Organization (WHO), each year approximately 3,000 to 5,000 children are born with a chromosome disorder.
Budding inclination for non-invasive techniques, mounting healthcare expenditure and programs focusing on boosting the alertness of NIPT are also facilitating the growth for the non-invasive prenatal testing market.
Absence of skilled professionals and consistency of test results in obese are the major challenges for the growth of non-invasive prenatal testing market. In addition, ethical hurdle is also hindering the growth of the market. Social-cultural values and norms, misuse of NIPT for minor conditions, accessibility and affordability, justice and fairness, permissibly legalizing termination of pregnancy due to a disability or any other undesired conditions, and others are some of the concerns associated with NIPT.
Globally, the manufacturing companies trying to enter the non-invasive prenatal testing market are required to maintain stringent regulatory standards. Moreover, the high level of capital requirement also poses a major barrier for the entry of new players.
Geographically, North America is the largest non-invasive prenatal testing market as in the region the occurrence of chromosomal abnormalities is increasing. Mounting maternal age, improved healthcare infrastructure, and boosting alertness programs are also up surging the growth of the North American non-invasive prenatal testing market. For instance, according to the Centre for Disease Control and Prevention (CDC) report on National Vital Statistics Report 2015, in the U.S., the mean age of mother at first birth was 25.8 years in 2012, and it has increased to 26 years in 2013.
Asia-Pacific is observed to witness the fastest growth in the market, due to mounting healthcare expenditure. In addition, boosting alertness programs and conferences are also creating a positive impact on the Non-invasive prenatal testing market growth in the region.
Key players in the non-invasive prenatal testing market are catering to the demand of these devices by investing in technologically advanced products in their product portfolio across the globe. In December 2017, PerkinElmer, Inc. acquired EUROIMMUN Medical Laboratory Diagnostics AG, to strengthen its position in China and other emerging countries. GE Healthcare, Perkinelmer, Inc., Koninklijke N.V., Qiagen, Pacific Biosciences of California, Inc., Agilent Technologies, Inc., and Beijing Genomics Institute are the key players offering non-invasive prenatal testing.
Pacific Biosciences of California, Inc., has acquired Omniome, to expand its market opportunities for sequencing innovative ways and add value to customers. Omniome has a novel approach to have an accurate short-read sequencing platform and enter large, fast-growing clinical applications such as oncology and non-invasive prenatal testing.
Source: VynZ Research